Latest Clinical & Research News
Specialty: Oncology
Using the world’s largest pharmacovigilance database, Eugene B. Cone, MD, Quoc-Dien Trinh, MD, and colleagues determined the risk of cardiac adverse events is increased substantially with abiraterone and not at all with enzalutamide.
Read More...
A retrospective study at the Brigham, led by Lisa Cooper, MD, and Laura N. Frain, MD, MPH, found that polypharmacy, potentially inappropriate medications, and frailty were not associated with complications after surgery for thoracic malignancies, but frailty was associated with increased length of hospital stay.
Read More...
Historically, stage 4 melanoma was considered incurable. In these cases, metastasectomy was performed for only as a palliative measure. But with recent advancements in systemic therapy, metastasectomy has emerged as an effective tool for extending the period of disease control and enhancing overall treatment response. Dana-Farber Brigham Cancer Center is at the forefront of this transformation.
By taking the brakes off the immune system and allowing it to attack cancer cells, checkpoint inhibitors have spurred significant advances in the treatment of many people with cancer over the past decade. But for patients who do not respond to these drugs — still the majority of people with cancer — alternative interventions are needed.
Andrew J. Schoenfeld, MD, orthopedic surgeon at Brigham and Women’s Hospital, Elena Losina, PhD, co-director of the Brigham’s OrACORe, and colleagues conducted the first cost-effectiveness analysis of surgery for spinal metastases that accounts for ambulatory function at presentation.
Read More...
Investigators at Brigham and Women’s Hospital have a clinical trial underway to evaluate the utility and efficacy of a novel blood test that screens women for ovarian cancer risk. Led by Kevin Elias, MD, of the Department of Obstetrics and Gynecology, the trial aims to enroll 500 women who are estimated to be at increased risk of developing the disease due to a family history of cancer or a known mutation in BRCA1, BRCA2 or another gene linked to ovarian cancer.
PARP inhibitors have become an important part of the arsenal for treating cancers caused by BRCA mutations — including breast cancer. Recently, clinical trials have begun looking at the combination of PARP inhibitors and immune checkpoint inhibitors in breast cancer, with the goal of making treatment more effective and longer lasting.
Immunotherapy with checkpoint inhibitor drugs is an emerging treatment for renal cell carcinoma. Now investigators from Brigham and Women’s Hospital have reported the results from lab research looking at a potential new way to boost the immune system’s ability to fight cancer.
Today’s cancer therapies are helping patients live longer. However, treatments including surgery, radiation, chemotherapy and certain targeted and immunological therapies increase the risk of developing cancer-associated thrombosis (CAT). Physicians at Brigham and Women’s Hospital’s Heart & Vascular Center are working with colleagues at Dana-Farber Cancer Institute (DFCI) to help prevent CAT and minimize its effect on timely cancer care.
While traditional tumor boards are common at most academic medical centers, Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) has taken its 10-year-old tumor board to the next level by integrating molecular pathology into their discussions.